Cleerly Scores $106M for Heart Disease Diagnosis Tools

Cardiovascular imaging company Cleerly announced it raised $106 million in a Series C funding round led by Insight Partners and Battery Ventures, with participation from pre-existing investors.

Cleerly is a digital healthcare company offering heart disease diagnosis solutions. It has developed a standard for coronary artery disease by combining quality clinical science with next-generation AI. Its AI-driven, non-invasive computed tomography (CT) imaging supports comprehensive phenotyping of coronary artery disease, leveraging scientific research based on millions of medical images.

The company plans to use the funds to "scale its commercial growth and clinical evidence generation," aiming to help healthcare professionals improve outcomes for patients with coronary artery disease. "We are thrilled to receive this investment from Insight Partners, marking a significant milestone for Cleerly," said Dr. James Min, founder and CEO of Cleerly. "We are very excited to see our purpose-driven mission come to life, making advanced cardiac care accessible to more patients and working toward our goal of eliminating heart attacks."

In 2022, Cleerly raised $192 million in Series C financing, bringing its total funding to $248 million. That round was led by T. Rowe Price and Fidelity Management & Research Company, with participation from Cigna Ventures, DigiTx Partners, Breyer Capital, Novartis, Vensana Capital, LRVHealth, New Leaf Ventures, Sands Capital, Piper Sandler’s Merchant Banking, Heartland Healthcare Capital funds, Mirae Asset Capital, and Peter Thiel. A little more than a year earlier, the company launched with $43 million in Series B funding.

Other companies in the cardiovascular imaging space include Caristo Diagnostics, which offers AI-enabled platforms to aid in predicting and diagnosing heart attack, stroke, and diabetes. Elucid Bioimaging, an AI medical technology company, develops tech aimed at providing physicians with a more precise view of atherosclerosis through its PlaqueIQ product, enabling personalized treatment based on actual disease rather than population-based risk. Similarly, HeartFlow offers an AI-powered, non-invasive heart care solution across the coronary computed tomography angiography (CCTA) pathway. Its suite of technologies includes FFRct Analysis, RoadMap Analysis, and Plaque Analysis.

Click here to read the original news story.